GHRP-6 10 mg is a lyophilized powder research peptide manufactured by Dragon Pharma, containing 10 mg of GHRP-6 (Growth Hormone Releasing Peptide-6) per 2 mL vial.
GHRP-6 is a synthetic hexapeptide that acts as a growth hormone secretagogue, stimulating pituitary GH release through ghrelin receptor (GHS-R1a) activation. It was the first GHRP developed with demonstrated in vivo activity and remains widely referenced in research contexts for its potent GH-releasing properties.
In clinical research settings, GHRP-6 has been studied for diagnostic applications and its effects on GH secretion across various metabolic states. It is not FDA-approved for any human use in the United States. In non-medical bodybuilding and performance contexts, GHRP-6 is commonly referenced for its GH-stimulating properties and pronounced appetite stimulation, making it a distinctive option among growth hormone secretagogues.
Compared to other GHRPs, GHRP-6 produces the most intense appetite stimulation and moderate elevations in cortisol and prolactin. Its GH-releasing potency is comparable to GHRP-2, but its side effect profile is less selective. These characteristics position GHRP-6 as a compound commonly referenced in bulking contexts where increased caloric intake is a goal.
GHRP-6 10 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. This form requires reconstitution with a suitable solvent such as bacteriostatic water before use.
GHRP-6 is a growth hormone secretagogue peptide that stimulates GH release through ghrelin receptor activation. Its profile is characterized by potent GH release, pronounced appetite stimulation, and moderate cortisol and prolactin effects.
GHRP-6 acts primarily on the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Activation of this receptor in the pituitary and hypothalamus triggers growth hormone release through mechanisms that are additive with GHRH analogs. GHRP-6 releases GH independently of hypothalamic GHRH and somatostatin.
The GH pulse produced by GHRP-6 is short-lived, typically peaking within 15–30 minutes after administration and returning to baseline within a few hours. This pulsatile release pattern mimics the body's natural GH secretion rhythm and is why multiple daily doses are commonly referenced in community protocols.
Compared to GHRP-2, GHRP-6 produces similar GH release with more pronounced appetite stimulation and slightly greater cortisol elevation. Compared to ipamorelin, GHRP-6 is more potent but less selective, with more noticeable effects on cortisol, prolactin, and appetite.
GHRP-6 produces a rapid, short-lived GH pulse after subcutaneous administration. This pulsatile pattern is distinct from the sustained elevation produced by GHRH analogs like CJC-1295 with DAC, and is why GHRP-6 is commonly stacked with GHRH analogs for synergistic effect.
Dragon Pharma offers several peptide preparations that are commonly referenced alongside GHRP-6 in research and bodybuilding contexts. The CJC-DAC provides a long-acting GHRH analog that is frequently stacked with GHRP-6 for enhanced GH release. GHRP-2 offers a more selective alternative with less pronounced appetite stimulation. Ipamorelin provides the most selective option with minimal cortisol and prolactin effects. For those interested in the GHRH analog without DAC, CJC 1295 No DAC/Ipamorelin is a pre-mixed combination option.
Published laboratory reports for GHRP-6 10 mg are shown below with the test date, measured concentration, and percentage of the product's 10 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
The information below is provided for educational reference only. GHRP-6 is not FDA-approved for any human use in the United States. All use in non-medical contexts falls outside approved indications.
In research and community settings, GHRP-6 is commonly referenced at microgram-level doses. The saturation dose for GHRP-6 is frequently cited around 100 mcg per injection, though doses up to 300 mcg are referenced in some protocols.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Research/Community (non-medical) | 100–300 mcg per injection | 2–3 times daily |
| Standard GH Pulse Protocol | 100 mcg | 2–3 times daily, fasting |
| Appetite-Focused Protocol | 200–300 mcg | 1–2 times daily, pre-meal |
| Combined with GHRH analog | 100 mcg GHRP-6 + 100 mcg Mod GRF 1-29 | 2–3 times daily |
GHRP-6 is commonly stacked with GHRH analogs such as CJC-DAC or Mod GRF 1-29 to produce synergistic GH release. The combination of a GHRP and a GHRH analog stimulates GH through complementary mechanisms, producing a larger pulse than either alone.
Community protocols typically reference cycles of 8–12 weeks followed by a 2–4 week break, though this practice is based on community experience rather than validated clinical protocols. Rotating between different GHRPs (such as GHRP-6 and Ipamorelin) is sometimes referenced to manage the appetite and cortisol effects of GHRP-6.
The most commonly referenced side effects of GHRP-6 include intense appetite stimulation, moderate cortisol and prolactin elevation, and injection-site reactions. Appetite stimulation is the most pronounced among GHRPs, beginning within 15–20 minutes of injection and lasting 1–2 hours.
Doses are typically timed away from food, as elevated blood glucose and insulin can blunt the GH response. Fasting for 2 hours before and 20–30 minutes after injection is commonly referenced in community protocols. Timing injections directly before planned meals is a standard strategy for managing the appetite effect.
GHRP-6 does not suppress endogenous testosterone production and therefore does not typically require post-cycle therapy in the way anabolic steroids do. However, some individuals may choose to use supportive compounds based on individual circumstances.
Since GHRP-6 works through the ghrelin receptor rather than directly affecting the hypothalamic-pituitary-gonadal axis, PCT is generally not considered necessary after GHRP-6 use alone.
Dosing strategies and cycle protocols should be adjusted based on individual factors. The information above is for educational reference and does not constitute medical advice.
GHRP-6 is not FDA-approved for any human use in the United States. It is a synthetic peptide that stimulates growth hormone release through ghrelin receptor activation.
GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release. It is not approved for therapeutic use in the United States. While GHRP-6 has been used in human clinical studies and has a well-characterized side effect profile, repeated daily use for performance or physique enhancement falls outside any approved framework.
Because GHRP-6 affects cortisol, prolactin, and appetite in addition to GH, its effects extend beyond GH release alone. Long-term safety data in humans is limited.
GHRP-6 is not FDA-approved for human use. Any use outside of approved research or diagnostic applications falls outside approved indications. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual.
GHRP-6 produces the most intense appetite stimulation among growth hormone secretagogues. Hunger begins within 15–20 minutes of injection and can be quite pronounced, particularly at doses above 200 mcg.
GHRP-6 produces moderate and transient cortisol and prolactin elevations. At standard doses, these effects are generally not clinically significant, but high-frequency dosing can produce cumulative cortisol exposure.
Other commonly referenced side effects include water retention, injection-site reactions, tiredness or drowsiness after injection, and occasional tingling or numbness in extremities. These effects are typically mild and self-resolving.
Individuals with active cancer or history of cancer, pituitary tumors or disorders, uncontrolled diabetes, or active infections at the injection site should avoid GHRP-6. The long-term effects of chronic GHRP-6 use have not been established.
Because GHRP-6 can affect cortisol and prolactin levels, individuals with conditions sensitive to these hormones should exercise particular caution. Pregnancy and breastfeeding are contraindications due to lack of safety data.
In research settings where GHRP-6 has been studied, monitoring has focused on GH response, cortisol, prolactin, and blood glucose levels. In non-medical contexts, individuals commonly reference periodic bloodwork to monitor hormonal and metabolic markers.
Laboratory testing of the product itself, such as the published potency report shown in the Lab Reports tab, is separate from any clinical monitoring of the individual.
Lyophilized GHRP-6 should be stored tightly sealed in its original container, protected from light, and kept at -20°C for long-term storage. The peptide is hygroscopic and should be allowed to equilibrate to room temperature before opening to prevent moisture uptake.
Keep all peptides and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
GHRP-6 10 mg by Dragon Pharma is supplied through the official distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
To verify your GHRP-6 10 mg product, use the security code on the vial label and cross-check it on the Dragon Pharma official site. Official presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve peptide stability and overall product integrity throughout shelf life.
Store the lyophilized (dry) powder tightly sealed in its original container, protected from light, and desiccated at -20°C for long-term storage. Brief handling at refrigerated or ambient conditions is acceptable provided the container is allowed to equilibrate to room temperature before opening to prevent moisture uptake.
GHRP-6 is hygroscopic and contains oxidation-prone tryptophan, so it must be kept dry and away from air and light to limit degradation. After reconstitution, store aliquots refrigerated at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles.
Keep out of reach of children. Follow proper handling and sterile technique when administering the product.
Answers to common questions about GHRP-6 10 mg, growth hormone release, product strength and laboratory testing.
GHRP-6 10 mg contains growth hormone releasing peptide-6, a ghrelin receptor agonist. In research settings it is used to stimulate GH release. In non-medical bodybuilding contexts, GHRP-6 is commonly referenced for its GH-stimulating properties and pronounced appetite stimulation, though such use falls outside approved indications.
Community protocols commonly reference GHRP-6 being injected 2–3 times daily at doses of 100–300 mcg per injection. Doses are typically timed on an empty stomach to maximize the GH response. The GH pulse from GHRP-6 is short-lived, which is why multiple daily doses are used to create multiple pulses.
GHRP-6 does not suppress endogenous testosterone production because it acts on the ghrelin receptor rather than directly affecting the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is therefore generally not considered necessary after GHRP-6 use alone.
GHRP-6 stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. This produces a pulsatile GH release that mimics the body's natural secretion pattern. GHRP-6 also produces pronounced appetite stimulation and moderate elevations in cortisol and prolactin.
The GH pulse from a single GHRP-6 injection typically peaks within 15–30 minutes and returns to baseline within a few hours. Appetite stimulation begins within 15–20 minutes and lasts 1–2 hours. Any cumulative effects on physique or recovery would develop over weeks of consistent use.
There is no single GH secretagogue that is universally best. GHRP-6 is the original GHRP and produces the most pronounced appetite stimulation. GHRP-2 offers comparable GH release with less appetite effect, while Ipamorelin is more selective with minimal cortisol and prolactin effects. The appropriate choice depends on individual goals.
Both GHRP-6 and GHRP-2 are growth hormone secretagogues that act on the ghrelin receptor. The main practical difference is that GHRP-6 produces significantly more appetite stimulation, while GHRP-2 has a more moderate effect. GHRP-6 also tends to produce slightly greater cortisol elevation at equivalent doses.
GHRP-6 is more potent for GH release but less selective, producing pronounced appetite stimulation and moderate cortisol and prolactin elevations. Ipamorelin is more selective with minimal effects on these hormones but produces a smaller GH pulse. GHRP-6 is positioned at the less selective end of the GHRP spectrum.
100 mcg is commonly referenced as the saturation dose for GHRP-6, meaning the point beyond which additional peptide produces diminishing GH response. Doses of 100–300 mcg per injection are typical in community protocols. The 10 mg vial contains 10,000 mcg total, providing 33–100 doses at these levels.
GHRP-6 10 mg is labeled at 10 mg of GHRP-6 per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.
Yes. A published laboratory report dated November 7, 2025 measured GHRP-6 10 mg at 10.38 mg, equivalent to 103.8% of its 10 mg label claim. The batch number for this report is #HDGH10.
The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.
Lyophilized GHRP-6 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.